The acquisition of Cardior Pharmaceuticals is seen as a stra...
The acquisition of Cardior Pharmaceuticals is seen as a strategic move by Novo Nordisk to establish a presence in the cardiovascular disease market, leveraging Cardior's RNA-targeting therapies and its lead compound, CDR132L.
Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Bln Purchase of Cardior Pharmaceuticals
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3150Followers
0Following
7904Visitors
Follow